Fig. 4: Impact of PB CTPC counts at diagnosis on the outcome of MGUS, SMM, and MM patients. | Blood Cancer Journal

Fig. 4: Impact of PB CTPC counts at diagnosis on the outcome of MGUS, SMM, and MM patients.

From: Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)

Fig. 4

TTP curves of MGUS and SMM grouped according to the absolute number of PB CTPC are shown in a and b, respectively. c and d display PFS and OS curves of MM patients grouped according to the absolute number of CTPC per μL of PB. In e and f PFS curves of treated myeloma (SMM and MM) patients grouped according to the absolute count of CTPC in PB detected at diagnosis and either the standard IMWG response criteria (e) or the BM MRD status (f) reached after therapy, are displayed, respectively. Patients who reached VGPR, CR/sCR or BM MRD-negativity after therapy and had low (black line) vs. high (blue line) levels of PB CTPC at diagnosis, are included in clusters 1 and 2 from both e and f, respectively; in turn, patients who did not reach VGPR, CR/sCR (e.g., PR, SD or PD) or BM MRD-negativity (e.g., BM MRD-positive cases) after therapy and had low (gray line) vs. high (red line) PB CTPC counts at diagnosis, are included in clusters 3 and 4 in e and f, respectively. TTP time to progression, PFS progression-free survival, OS overall survival, PC plasma cell, CTPC circulating tumor PC, NR not reached, PB peripheral blood MGUS monoclonal gammopathy of undetermined significance, SMM smoldering MM, MM symptomatic multiple myeloma, IMWG International Myeloma Working Group, VGPR very good partial response, CR complete response, sCR stringent complete response, PR partial response, SD stable disease, PD progressive disease

Back to article page